Standard BioTools Inc. LAB NASDAQ

Standard BioTools Inc. (LAB) reported total assets of $567.75M and total liabilities of $143.46M for fiscal year 2025, resulting in total equity of $424.29M.

The company held $187.58M in cash and short-term investments. Total debt stood at $30.83M, with net debt of $-87.39M. The Debt-to-Equity (D/E) ratio was 0.07 (conservative).

Current ratio is 4.19, indicating strong short-term liquidity. Interest coverage is -3588.7x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (43/100) — Total assets $567.75M and equity $424.29M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0.07 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

OLK

Olink Holding AB (publ)

$26.08

+0.31%

GTH

Genetron Holdings Limited

$4.03

+0.12%

MDXH

MDxHealth SA

$2.31

+1.76%

FONR

FONAR Corporation

$18.77

+0.05%

STIM

Neuronetics, Inc.

$1.39

-2.80%

BDSX

Biodesix, Inc.

$12.66

+4.28%

SERA

Sera Prognostics, Inc.

$2.18

+1.87%

DRIO

DarioHealth Corp.

$7.51

-0.66%